Get the Stockscreener App
3.96
2.94%
-0.12
After Hours:
3.83
-0.13
-3.28%
Salarius Pharmaceuticals Inc stock is traded at $3.96, with a volume of 415.14K.
It is down -2.94% in the last 24 hours and down -25.14% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$4.08
Open:
$4.01
24h Volume:
415.14K
Relative Volume:
1.45
Market Cap:
$2.02M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.6168
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
+0.76%
1M Performance:
-25.14%
6M Performance:
-57.84%
1Y Performance:
-81.41%
1-Day Range:
$3.86
$4.20
1-Week Range:
$3.84
$4.60
52-Week Range:
$3.64
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
3.96 | 3.85M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Applying Elliott Wave Theory to Salarius Pharmaceuticals Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
Will Salarius Pharmaceuticals Inc. stock benefit from green energy trendsBond Market & Weekly Chart Analysis and Trade Guides - newser.com
How to recover losses in Salarius Pharmaceuticals Inc. stock2025 Price Momentum & Low Drawdown Investment Ideas - newser.com
Can machine learning forecast Salarius Pharmaceuticals Inc. recoveryPortfolio Update Report & Precise Buy Zone Identification - newser.com
How institutional ownership impacts Salarius Pharmaceuticals Inc. stockOil Prices & AI Forecast Swing Trade Picks - newser.com
Salarius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Ahead of Merger with Decoy Therapeutics - Quiver Quantitative
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements - GlobeNewswire
Can Salarius Pharmaceuticals Inc. stock deliver sustainable ROETrade Volume Report & Weekly Return Optimization Alerts - newser.com
Real time alert setup for Salarius Pharmaceuticals Inc. performancePortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
Salarius Pharmaceuticals Inc. stock momentum explainedTrade Ideas & Expert Curated Trade Ideas - newser.com
Long term hold vs stop loss in Salarius Pharmaceuticals Inc.July 2025 Catalysts & Weekly Momentum Picks - newser.com
What data driven models say about Salarius Pharmaceuticals Inc.’s futureJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Is Salarius Pharmaceuticals Inc. (FP10) stock positioned for secular growth2025 Risk Factors & Consistent Profit Trading Strategies - newser.com
Why Salarius Pharmaceuticals Inc. (FP10) stock could break out in 2025Quarterly Market Review & Momentum Based Trading Signals - newser.com
Ewing Sarcoma Market Report 2034: Epidemiology Insights, Pipeline Developments, and Key Regulatory Approvals (FDA, EMA, PMDA) | Published by DelveInsight | Featuring Leading Companies: Salarius Pharma - Barchart.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading 1% Higher – Here’s Why - Defense World
Salarius Pharmaceuticals Awaits Nasdaq Compliance Confirmation - TipRanks
What Fibonacci levels say about Salarius Pharmaceuticals Inc. reboundQuarterly Trade Review & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Salarius Pharmaceuticals Inc.Market Movers & Daily Volume Surge Trade Alerts - newser.com
Risk vs reward if holding onto Salarius Pharmaceuticals Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
How higher bond yields impact Salarius Pharmaceuticals Inc. (FP10) stockTrade Volume Summary & Verified Technical Trade Signals - newser.com
Is Salarius Pharmaceuticals Inc. building a consolidation baseWeekly Stock Recap & Technical Buy Zone Confirmations - newser.com
Should you wait for a breakout in Salarius Pharmaceuticals Inc.2025 Market Outlook & Safe Capital Growth Tips - newser.com
What momentum shifts mean for Salarius Pharmaceuticals Inc.2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):